Irinotecan News and Research

RSS

Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Acne-like rash linked to effectiveness of new targeted cancer treatment – cetuximab

Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment – cetuximab – has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

30 Sep 2004

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Erbitux (cetuximab), offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an article written by two Mayo Clinic cancer researchers published in the current edition of the New England Journal of Medicine.

21 Jul 2004

Drug helps patients with metastatic colorectal cancer

A drug designed to cut off a tumor’s blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

3 Jun 2004

Drug to extend lives of colorectal cancer patients

A drug designed to cut off a tumor's blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

2 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004